IWave Wins Bronze Stevie® Award in 2020 Stevie Awards for Sales & Customer Service

iiWave fundraising solution for nonprofits

iWave: Changing the Future of Fundraising for Nonprofits

Stevie bronze level award logo for sales & customer service

iWave Wins Bronze Stevie Award in Sales & Customer Service

iWave, the industry’s top-rated fundraising intelligence solution, was presented with a Bronze Stevie® Award in the BEST CUSTOMER SATISFACTION STRATEGY category

CHARLOTTETOWN, PRINCE EDWARD ISLAND, CANADA, March 3, 2020 /EINPresswire.com/ — iWave, the industry’s top-rated fundraising intelligence solution, was presented with a Bronze Stevie® Award in the BEST CUSTOMER SATISFACTION STRATEGY category in the 14th annual Stevie Awards for Sales & Customer Service on February 28, 2020.

The Stevie Awards for Sales & Customer Service are the world’s top honors for customer service, contact center, business development and sales professionals. The Stevie Awards organizes eight of the world’s leading business awards programs, also including the prestigious American Business Awards® and International Business Awards®.

The awards were presented to honorees during a gala banquet on Friday, February 28 at Caesars Palace in Las Vegas, NV. More than 600 executives from the U.S.A. and several other nations attended.

More than 2,600 nominations from organizations in 48 nations of all sizes and in virtually every industry were evaluated in this year’s competition. Winners were determined by the average scores of more than 180 professionals worldwide on seven specialized judging committees.

“We are honored to have received this international recognition amongst some of the most recognized and respected companies in the world, “ said iWave CFO Colin Paddington. “Our team is committed to providing only the best products and services to prospect development and fundraising professionals.”

“iWave puts its clients first in everything we do”, said iWave President and CEO Ross Beattie. “We are always looking ahead. Our entire team, from product developers to client success managers, are all working together to deliver solutions that exceed our clients’ needs and expectations. But we are never satisfied.”

“At iWave, we pride ourselves on being at the forefront of nonprofit fundraising innovation with an agile development process that leverages client and industry insights to continuously bring more value, along with the best customer service in the industry to our non-profits, higher education, and healthcare organizations”, Beattie said. “We will have a number of new announcements in 2020 that will continue to ensure iWave is the leading provider of nonprofit fundraising solutions.”

About iWave
iWave, the industry’s top-rated fundraising intelligence platform, enables nonprofit organizations to fundraise with confidence. In a new era of nonprofit fundraising, iWave solves critical challenges facing fundraising professionals today: how to identify, qualify and retain donors to raise more major gifts. iWave’s intuitive and easy-to-use solutions give access to the industry’s highest quality wealth and philanthropic information so you can determine who to ask, how much to ask for, and when to ask. Since 1991, over 6000 clients, including many of the largest education, healthcare and nonprofit organizations in the World, have relied on iWave to power their fundraising efforts. Learn more about iWave at http://www.iwave.com Visit our website and blog, follow us on Twitter and LinkedIn and like us on Facebook.

About The Stevie Awards
Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Dana Prestigiacomo
iWave
+1 203-505-8485
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

OMNIBotics® Hits Global Milestones of 25,000 Total Knee Replacements, with 5,000 Using Unique BalanceBot™ Technology

Profile view of the OMNIBotics BalanceBot - a ligament tensioning device for total knee arthroplasty

BalanceBot™ robotic ligament tensioning device for total knee arthroplasty

OMNIBotics robotic cutting guide, mounted to the femur.

OMNIBotics robotic cutting guide

Corin: Connected Orthopedic Insight

Corin: Connected Orthopedic Insight

5,000 OMNIBotics TKA procedures have benefited from BalanceBot. Designed to help target precise ligament balance for better outcomes with reduced pain.

The experience gained from over 5,000 surgeries with the BalanceBot has been invaluable to understanding soft tissue balancing and its effects on patient outcomes and future advancements.”

— Chris Plaskos, PhD, Corin’s VP of Global Clinical Innovation

BOSTON, MA, UNITED STATES, March 3, 2020 /EINPresswire.com/ — OMNIBotics® Hits Global Milestone of 25,000 Total Knee Replacements, with 5,000 Using Unique BalanceBot™ Technology

• A total of 25,000 OMNIBotics total knee arthroplasty (TKA) procedures performed
• 5,000 OMNIBotics procedures have benefited from the latest soft tissue balancing technology, BalanceBot
• Major milestone in delivering more precise ligament balance for better patient outcomes with reduced pain(1,2)

[Boston, MA. March 3rd, 2020] Corin, the global orthopaedic technology business, is proud to announce its OMNIBotics robotic-assisted platform has recently completed 25,000 total knee arthroplasties(TKA), including 5,000 procedures using the BalanceBot ligament balancing robotic device.

The BalanceBot uniquely enables surgeons to balance knee joints by understanding feedback from soft tissue and ligaments throughout the entire range of motion.

The BalanceBot is used in the Predictive Balance™ technique in order to accurately predict the effect that implant positioning will have on knee gaps in flexion, extension and midflexion. More precise ligament balance allows surgeons to target knee gaps that correlate with better outcomes and less pain(1,2). The platform can also be used intra-operatively to assess the patient's overall knee stability throughout the full range of motion with the joint in situ.

Dr. Jeffrey H. DeClaire, from the DeClaire LaMacchia Orthopedic Institute, in Rochester, Michigan who is one of the first orthopaedic surgeon to use BalanceBot says,

“OMNIBotics, and the use of the BalanceBot device, is a significant improvement to the field of knee replacement. The ability to plan implant position to best balance the knee’s soft tissues using the Predictive Balance software, on top of the consistency and reproducibility that comes with robotics, is remarkable. The immediate results are noticeable and I’m excited to continue monitoring my patients and track their recoveries.”

Features of OMNIBotics
• Robotic-assisted ligament tensioning – accurately predict and consistently achieve post-operative gap balance(3)
• Robotic guide positioning – more efficient and accurate femoral cuts in comparison to conventional cut blocks(4)
• OMNIBotics Bone Morphing™ 3D modelling – intraoperative technology creates a 3D model of bones without additional CT or MRI scans
• Supports standardized care pathway – reduce care costs, with further associated reductions in cost and discharge to sub-acute rehabilitation facilities(5)
• Easy to implement and use – short learning curve for clinicians with comparable procedure times to conventional TKA(6)

Reducing post-operative complications
Up to 20% of TKA patients report dissatisfaction associated with their knee replacement, yet do not require revision surgery(7). Often this dissatisfaction can lead to increased post-operative visitations, physical therapy and manipulations under anesthesia. Through multi-centre studies, Corin can confirm high 1-year patient satisfaction scores of 95.5% from BalanceBot procedures compared to 81.4% for non-robotic assisted procedures.(2)

"The experience gained from over 5,000 surgeries with the BalanceBot has been invaluable to understanding soft tissue balancing and its effects on patient outcomes and future advancements. As a company, we are proud to have reached this major milestone and we continue to provide our customers with innovative technologies which are revolutionizing joint replacement for patients and surgeons.” says, Chris Plaskos, PhD, Corin’s VP of Global Clinical Innovation.
-ENDS-

Media information
For more information, interviews, and images please contact ROAD Communications on corin@roadcommunications.co.uk or +44 (0)208 995 5832.

About Corin
Corin is a fast-growing international orthopaedic company with a vision is to revolutionize orthopaedics by gaining, understanding and sharing insight at every stage of the arthroplasty experience. The unique combination of advanced technologies, shared knowledge and clinically proven implants is intended to deliver better outcomes and maximize value for patients, surgeons and healthcare providers.

References

1. Wakelin E, Shalhoub S, Lawrence J, Koenig JA, Ponder CE, DeClaire JH, Randall A, Keggi J, Plaskos C. (2019). The impact of intra-operative coronal mid-flexion and flexion balance on early post-operative pain in TKA. AAHKS Annual Meeting 2019
2. Keggi JM, Lawrence JM, Randall AL, Declaire JH, Shalhoub S, Plaskos C Early Clinical Outcomes of a Novel Predictive Ligament Balancing Technique for Total Knee Arthroplasty CAOS Int’l Conference 2019;
3. Shalhoub, S., Lawrence, J.M., Keggi, J.M., Randall, A.L., DeClaire, J.H. and Plaskos, C. (2019). Imageless, robotic-assisted total knee arthroplasty combined with a robotic tensioning system can help predict and achieve accurate postoperative ligament balance. Arthroplasty Today, 5(3), pp.334–340.
4. Koulalis, D., O’Loughlin, P.F., Plaskos, C., Kendoff, D., Cross, M.B. and Pearle, A.D. (2011). Sequential versus automated cutting guides in computer-assisted total knee arthroplasty. The Knee, 18(6), pp.436–442.
5. Koenig, J.A. and Plaskos, C. (2019). Total Knee Arthroplasty Technique: OMNIBotics. Robotics in Knee and Hip Arthroplasty, pp.167–183.
6. Keggi JM, Plaskos C. Learning Curve and Early Patient Satisfaction of Robotic-Assisted Total Knee Arthroplasty. ICJR Transatlantic Orthopaedic Conference, 2016
7. Golladay, G.J., Bradbury, T.L., Gordon, A.C., Fernandez-Madrid, I.J., Krebs, V.E., Patel, P.D., Suarez, J.C., Higuera Rueda, C.A. and Barsoum, W.K. (2019). Are Patients More Satisfied With a Balanced Total Knee Arthroplasty? The Journal of Arthroplasty, 34(7), pp.S195–S200.

Daniel Cipolletti
Corin Group
+1 774-226-1843
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Surgical Tumor Ablation Market to be Worth Around 2,256 Million By 2025 – Zion Market Research

Surgical Tumor Ablation Market

Surgical Tumor Ablation Market

Global Surgical Tumor Ablation Market expected to generate around USD 2,256 million by 2025, at a CAGR of around 11.6% between 2019 and 2025

Global Surgical Tumor Ablation Market expected to generate around USD 2,256 million by 2025, at a CAGR of around 11.6% between 2019 and 2025”

— Zion Market Research

NEW YORK, NEW YORK, UNITED STATES, March 3, 2020 /EINPresswire.com/ — Zion Market Research has published a new report titled “Surgical Tumor Ablation Market by Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, and Others) and by Application (Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global surgical tumor ablation market was approximately USD 1,044 million in 2018 and is expected to generate around USD 2,256 million by 2025, at a CAGR of around 11.6% between 2019 and 2025.

Tumor ablation is referred to as a minimally-invasive technique for the treatment or destruction of cancer cells. Certain probes like needles are used to freeze or burn cancerous cells without conventional surgical treatment. Increasing prevalence of cancer across the globe is creating the demand for an efficient and effective treatment that can improve patient health at a relatively lower time, with minimal invasion and pain and at affordable costs. This is the primary growth driver of the global surgical tumor ablation market. Other prominent factors boosting the surgical tumor ablation market growth are the rising awareness about the advantages of tumor ablation over conventional treatment methods and growing investments made in tumor ablation techniques worldwide. Furthermore, technological advancements related to the thermal ablation technique are also expected to fuel the surgical tumor ablation market growth in the upcoming years. However, the change in government reforms may hinder the global surgical tumor ablation market growth in the years ahead.

Get Sample of this Research Report – https://www.zionmarketresearch.com/sample/surgical-tumor-ablation-market

The global surgical tumor ablation market is fragmented on the basis of technology and application. Based on technology, the market includes cryoablation, microwave ablation, radiofrequency ablation, and others. By technology, the microwave ablation segment is expected to register the highest growth rate in the future, due to product-related technological advancements and benefits like consistency in high temperature, lower procedural pain, larger tumor ablation volume, and optimal heating of the cystic mass.

By application, the global surgical tumor ablation market is categorized into lung cancer, prostate cancer, breast cancer, liver cancer, and others. The liver cancer segment is estimated to hold a notable market share in the future, whereas the lung cancer segment is expected to show a high CAGR over the forecast time period. According to the American Cancer Society Liver, cancer is one of the most common diseases in Southeast Asia and sub-Saharan Africa than in the U.S. More than 700,000 people are diagnosed with liver cancer annually across the globe. Liver cancer is a major root of cancer deaths globally, accounting for more than 600,000 deaths every year.

The North American surgical tumor ablation market is anticipated to continue its regional dominance over the forecast timeframe as well. This can be attributed to Well-planned and implemented healthcare reforms, high adoption of advance therapeutic procedure, increasing prevalence of cancer, and high purchasing power of the regional population. The Asia Pacific surgical tumor ablation market is proposed to register the highest growth rate over the projected timeframe, owing to the increasing cancer prevalence, rising disposable income of the regional population, and a growing number of government initiative with favorable reimbursement policies.

Browse TOC of this Research Report – https://www.zionmarketresearch.com/toc/surgical-tumor-ablation-market

Some key players of the global surgical tumor ablation market are Galil Medical, Misonix, HealthTronics, AngioDynamics, Covidien, Boston Scientific Corporation, Medtronic, SonaCare Medical, EDAP TMS, and NeuWave Medical.

This report segments the global surgical tumor ablation market into:

Global Surgical Tumor Ablation Market: Technology Analysis

Radiofrequency Ablation
Microwave Ablation
Cryoablation
Others

Global Surgical Tumor Ablation Market: Application Analysis

Liver Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Others

Global Surgical Tumor Ablation Market: Regional Analysis

North America
U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa

Browse more Healthcare Market Research Reports – https://www.zionmarketresearch.com/category/healthcare

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Kalpesh Deshmukh
Zion Market Research
+1 855 465 4651
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

SafeCare Magazine Releases In$ulin Sticker Shock Edition

IN$ULIN STICKER SHOCK

Americans Deserve Better Drug Pricing

The reality for 10 million adult Americans with diabetes is rationing of insulin and struggling to pay for it”

— Yisrael Safeek, MD, MBA, CEO, The SafeCare Group

LEXINGTON, KY, USA, March 3, 2020 /EINPresswire.com/ — SafeCare magazine announced today the release of its IN$ULIN STICKER SHOCK edition focusing on the unaffordability of insulin. This edition delves into how the cost of insulin has risen in the past decade over three-fold.

“The reality for 10 million adult Americans with diabetes is rationing of insulin and struggling to pay for it,” said Yisrael Safeek, MD, MBA, CEO, The SafeCare Group. “15 years ago, a patient with diabetes might have paid $175.57 for a 20-milliliter vial of the long-acting insulin Humulin R U-500. Today, she’d shell out $1,487 for the same tiny vial.”

The cover story article “Expensive Insulin – How Insulin Prices Tripled” contrasts the statements and actions of Alex M. Azar II, the Secretary of Health and Human Services, as the President of Eli Lilly and in his current position. During the five years that he led Eli Lily, the price of insulin tripled. Since being the head of HHS, he has said “drug prices are too high” but they continue to rise, even insulin.

“To cope with high insulin prices, patients are forced into desperate measures including reducing the dose, skimping on utility payments, and even cutting back on groceries,” stated SafeCare Editor-in-Chief Linda Christmann, MD, MBA. “The logical consequences of this have followed: complications of diabetes including blindness, renal failure, amputations and even death, not to mention ruining family finances.”

Another article “Stayed Overseas for Insulin – Went For School” is a compelling story of an American who attended graduate school in Germany and found her monthly bill for insulin and supplies which had been about $200 per month in the US, dropped to less than $4 per month. Never having to worry about affording her essential medication has led her to stay on in the country.

Yet another article "Cheaper Drug Imports – Gimmick or Open for Business” discusses a strategy that many Americans have adopted to afford medications; buy them abroad.

This edition also include articles that discuss topics essential for healthcare leaders, potential complications of hospital care, and infectious disease threats.

We appreciate our readers and strive to deliver information on the people, ideas, organizations and novel technologies affecting safe, efficient, and quality healthcare to the sector’s most influential leaders. Thus, feedback from subscribers and advertisers alike are welcome, as their input is highly valued.

About The SafeCare Group®
The SafeCare Group is focused on helping patients by extending our products across their healthcare journey – everything from finding a hospital, writing reviews, and staying connected afterwards. In 2019, The SafeCare Group launched RateAHopsital.com to allow patients to share care experiences, and in 2013, the 100 SafeCare Hospitals® rankings were created to empower healthcare consumers. Since 2016, The SafeCare Group invested heavily into Artificial Intelligence (AI) software. Known as Intelligent Healthcare™ software by leveraging machine learning and deep-learning capabilities, SafeCare AI® Suite fosters a new generation of AI applications, which are able to sense, reason, act and adapt, to address a range of healthcare challenges in areas such readmissions, medical errors, infections, cost, and outpatient utilization. Since 2014, SafeCareSoft® SaaS solutions enable hospitals to take advantage of disruptive healthcare software known as Softwaring Healthcare Excellence® that optimize hospital ratings and regulatory accreditation. The SafeCare Group® was founded in 2010. For more information about The SafeCare Group, visit www.safecaregroup.com

Siva Sankar
The SafeCare Group
+1 800-700-9481
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

HIP Video Promo presents: Kellie-Anne premieres new "Legacy" music video on Talent In Borders to raise ALS awareness

Kellie-Anne

Her powerful new single is “Legacy,” which is very close to Kellie-Anne’s heart, as her close family friend, John, lives with ALS (Lou Gehrig’s disease).

WEEHAWKEN, NJ, USA, March 3, 2020 /EINPresswire.com/ — Watch the new "Legacy" music video on Talent In Borders

Kellie-Anne
"Legacy"

About Kellie-Anne

At just 17, Kellie-Anne's already got a traveler's wisdom, a wanderer's honesty, and perspective. The pop and soul singer/songwriter recently transplanted to NYC by way of Dubai, by way of Quebec City, so she understands that there are a lot of stories that she has the ability and the obligation to tell. And she's got the innate ability to relate instantly, to fill someone else's shoes while still managing to speak from her heart. She's released singles written to empower the victims of bullying and encourage anyone with a lifelong dream growing cold on the backburner. Able to turn heads and catch ears in venues ranging from international music festivals to legendary Greenwich Village clubs like The Bitter End to the Voice Kids in Canada, she proudly accepts comparisons to artists like Sia, Taylor Swift, and Ed Sheeran. With a top 5 chart placement on Reverbnation and over 140k streams on Spotify, the time is right to release her strongest offering yet, the epic piano ballad "Legacy."

A slowly building tour de force riding on Kellie-Anne moving, cathartic vocals and emotive piano melodies, the true power of "Legacy" lies in its lyrics. Kellie-Anne's close family friend, John, lives with ALS, better known as Lou Gehrig's Disease, an incurable condition that slowly robs you of the ability to perform even the simplest tasks. It's as human a trait as the will to live, to want to leave something behind after you've shuffled off: descendants, art, or simply a lasting impression upon those who knew you. Sadly, ALS limits one's options when it comes to their legacy. The story of "Legacy," told by Kellie-Anne's rich, octave-climbing singing, is the indelible mark John is leaving. This is a rare song that is powerful in every way.

Kellie-Anne, who also directed, and producer Rob Fitzgerald achieve a powerful subtlety and pull rock-solid performances out of the actors in his videos, especially considering these aren't actors at all. Her friends and relatives stepped up to portray a family at home, navigating the everyday hurdles that ALS throws their way. Kellie-Anne's performance of "Legacy" here is simple, striking, elegant — her sonorous voice itself seems to fill the frame when the camera rests on her. The video comes full circle in the coda, which features John giving his thoughts on the track, and as you watch and listen, you realize that this is more than just a song, more than just a video, it's a once-in-a-lifetime partnership, a legacy like no other. Art like this is a powerful motivator.

More info about ALS via ALSA
More info about Kellie-Anne on HIP Video Promo

Andy Gesner
HIP Video Promo
+1 732-613-1779
email us here


Source: EIN Presswire

Global Color Cosmetics Market Industry Analysis, Size, Share, Growth, Trends and Forecast 2020-2026

WiseGuyReports.com adds “Global Color cosmetics Market Size study, product type, distribution channel and Regional Forecasts 2020-2026” reports to its database.

PUNE, MAHARASTRA, INDIA, March 3, 2020 /EINPresswire.com/ — Color Cosmetics Market:

Executive Summary

Global Color cosmetics Market is valued approximately at USD 54.89 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 6.19% over the forecast period 2019-2026. Color cosmetics is a broad term that encompasses diverse categories of products for skin, eyes, cheeks and lips. These cosmetic products include wide range of products such as foundations, nail paint, lipsticks, eyeliner, bronzers. Rising consciousness among people regarding appearance coupled with technological advancement in the color cosmetics are considered as key driving forces of the market growth. Apart from this, increasing spending on personal grooming coupled with increasing demand for color cosmetics to reduce ae related skin imperfections are further contributing towards market. As per Statista, the per capita spending on color cosmetics in Brazil on an average was about $9.5 per person in 2016 that is expected to be valued about $10.8 per person by 2021. The Europe cosmetics industry report 2019, states that the European consumers spend on an average about $149 per year on purchasing cosmetics products. Similarly, in South Korea, consumer spending on cosmetics shopping has increased to $6.9 billion in 2016 from $6.3 billion in 2014. This, growth in consumer spending on cosmetic product is increasing promoting the adoption of color cosmetics across the globe. Moreover, rising concern over harmful effects associated with conventional cosmetic products is shifting consumer preference towards the usage of organic color cosmetics. As in conventional cosmetics chemical substances such as asbestos, hexachlorophene, arsenic, lead and mercury compounds leading to adverse health implication. Whereas benefits with organic cosmetics include no irritation, no harmful substances and environmentally friendly products are encouraging the utilization of organic color cosmetics. Hence, significant increase in the adoption of organic color cosmetics is expected to create huge growth prospects in the market over the forecast period. However, stringent regulatory norms associated with manufacturing color cosmetics is projected to create significant barrier in the color cosmetic market growth.

Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5025103-global-color-cosmetics-market-size-study-by-product

The regional analysis of global Color cosmetics market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia-Pacific is leading regions and also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such increasing workforce population, disposable income along with technological advancement in the color cosmetics would create lucrative growth prospects for the Color cosmetics market across Asia-Pacific region.

Major market player included in this report are:
L'Oreal Group
Unilever
Estee Lauder
Coty
Shiseido Company, Limited Beiersdorf
Revlon
Amorepacific Group Kao corporation
Avon

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By product type:
Face
Lip
Eye

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Global Color cosmetics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Global Color cosmetics Market Definition and Scope

Chapter 3. Global Color cosmetics Market Dynamics

Chapter 4. Global Color cosmetics Market: Industry Analysis

Chapter 5. Global Color cosmetics Market, by Product Type

Chapter 6. Global Color cosmetics Market, by Distribution channel

Chapter 7. Global Color cosmetics Market, Regional Analysis

Chapter 8. Competitive Intelligence

Chapter 9. Research Process

Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/5025103-global-color-cosmetics-market-size-study-by-product

NORAH TRENT
WiseGuy Research Consultants Pvt. Ltd.
08411985042
email us here


Source: EIN Presswire

Baby Food Product Market 2020 Global Industry – Key Players Analysis, Sales, Supply, Demand and Forecast to 2026

Wiseguyreports.Com Publish New Research Report On-“Baby Food Product Market 2020 Global Analysis, Size, Share, Trends, Opportunities and Growth, Forecast 2026”

PUNE, INDIA, March 3, 2020 /EINPresswire.com/ —

Baby Food Product Market 2020

Industry Overview
The basic analysis of the Baby Food Product market has been done that gives a brief overview of the scope of the market and the research methodology. This overview also presents the key trends and developments in the market with an exhaustive industrial analysis of the drivers, restraints and other growth opportunities. For examining the intricacies of the Baby Food Product market, experts have studied and deeply analysed the latest industry trends in various regions of the world. The report also offers the price margins of the product along with the risks and constraints faced by the key players.

Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/4927252-global-baby-food-product-market-research-report-2020

Key players
In relation to the key players, special focus has been on the competitive scenario of the market with the analysis of the new trends and changes been undergone by the companies. Several prominent vendors are contributing to the overall changes in the market landscape, which includes high-end as well as new-entry players. The involvement of the key players plays an essential role in the growth of the global Baby Food Product market.

The top players covered in Baby Food Product Market are:
Abbott Nutrition
Mead Johnson Nutritionals
Kraft Foods
Nestle Group
Stonyfield Farm
Yummy Spoonfuls
Plum PBC
Alimentos Heinz

Drivers & Risks
A comprehensive analysis of the product/services has been done to give a clear understanding of the basic market dynamics that mould the Baby Food Product market. The report also evaluates the numerous trends and pricing history that affect the market value of the product/service. The various number of potential growth factors, risks and opportunities are also considered based on the type, application and other segmentation of the market.

Regional description
The forecast analysis has been done of the Baby Food Product market on a global, regional and company level. Taking a closer look at the industry trends, the report focuses on the contribution of various regions such as North America, Europe, Asia-Pacific, the Middle East, and Africa. These regions are expected to be the fastest-growing market during the forecast period, owing to the numerous business expansions by the market players, with increasing government initiatives that are boosting the growth of the Baby Food Product market.

Method of research
A compilation of first-hand information by the industry experts shows that Porter’s Five Force model has been used. It suggests that an in-depth analysis of the market is being done, focusing on the current inputs from industry experts and industry participants. The SWOT analysis has also been conducted that gives an idea about the explicit details of the Baby Food Product market. An in-depth study of the main strengths, risks, competitive strategies, and opportunities have also been mentioned in the global report.

For Customisation and Query @ https://www.wiseguyreports.com/enquiry/4927252-global-baby-food-product-market-research-report-2020

Table of Contents –Analysis of Key Points
1 Market Overview
2 Manufacturers Profiles
3 Global Baby Food Product Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
4 Global Baby Food Product Market Analysis by Regions
5 North America Baby Food Product by Country
6 Europe Baby Food Product by Country
7 Asia-Pacific Baby Food Product by Country
8 South America Baby Food Product by Country
9 Middle East and Africa Baby Food Product by Countries
10 Global Baby Food Product Market Segment by Type
11 Global Baby Food Product Market Segment by Application
12 Baby Food Product Market Forecast (2020-2026)
13 Sales Channel, Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
List of Tables and Figures
Continued…..

Norah Trent
wiseguyreports
646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Point-of-Care Testing 2020 Market Research and Development, Future Outlook Analysis To 2024

WiseGuyReports.Com Publish a New Market Research Report On –“ Point-of-Care Testing 2020 Market Research and Development, Future Outlook Analysis To 2024”.

PUNE, INDIA, March 3, 2020 /EINPresswire.com/ —

Point-of-Care Testing Market 2020

Description: –

Point-of-Care testing can be defined as the medical diagnostic testing performed outside the clinical laboratory near to the place where the patient is receiving treatment. This type of testing is performed by non-laboratory personnel and the results are used for clinical decision making. The Point-of-Care tests have immense potential to improve global health, and to eventually reduce public and national spending on health.

The Point-of-Care testing devices have now found applications in a large number of medical conditions. Due to its increased usage in the field of critical care settings to deliver decentralized, patient-centric healthcare to the patients, the projections for the global Point-of-Care testing market is expected to witness a rapid growth. It is predicted that by 2022, the global Point-of-Care testing market will reach U$$ 30 Billion.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/1706520-global-point-of-care-testing-market-by-product-glucometers-bge-analyzers

For more information or any query mail at sales@wiseguyreports.com

Key Players

Becton, Dickinson and Company
Roche Diagnostics
Siemens Healthineers
Danaher Corporation
Abbott Laboratories
Johnson & Johnson

According to the global Point-of-Care Testing market report, a brief overview of the market size in terms of various parameters have been mentioned. This overview includes an exhaustive analysis of the latest trends and shifts that are prevalent in the industry. In particular, an informative market introduction in addition to the research objectives is also presented in the market report. An executive summary in terms of historical data and prospects have been scrutinized by the data experts, along with the latest industry trends in the key regions. The report also presents the market share, volume and risk factors that influence the growth of the Point-of-Care Testing market.

Drivers & Risks

An insight into the market status of the product/service has been given where 2020 is the base year and the forecast period extends from 2020 to 2024. Various factors and principles govern the market, providing a basic understanding of the drivers and risk factors that influence the growth of the global market. The growing demand from the key regions and potential industries, challenges, impacts and the changing trends in the market have been studied to have a grasp over the overall market scenario.

Regional Description

The future forecast of the Point-of-Care Testing market has been analyzed on a global level, regional level, and company level. Insightful analysis and research have been done focusing on the regions of Asia-Pacific, Europe, North America, Latin America, Middle East & Africa. These regions have been studied, the manufacturing sites, product types by manufacturers, sales area and other factors have also been evaluated that could benefit the market in the long run.

Method of Research

The Point-of-Care Testing market report shows that thorough research has been conducted by the research experts based on various parameters that form Porter’s Five Force Model. The research study has also pointed towards the growth pockets that have the potential to take the market forward and optimally utilize the resources at hand. Additionally, the experts have also conducted SWOT based analysis that delivers explicit details about the Point-of-Care Testing market. The in-depth study of the key players of the market has also been done, including the company details, products/services offered, sales, revenue, and gross margins that help to identify and accelerate the profit and growth opportunities in the Point-of-Care Testing market. With a better understanding of all these factors, the future aspects of the key companies worldwide can also be understood.

Enquiry About Report @ https://www.wiseguyreports.com/enquiry/1706520-global-point-of-care-testing-market-by-product-glucometers-bge-analyzers

Table of Contents – Major Key Points

1. Analyst View

2. Research Methodology

3. Industry Catalysts

4. Indian Popcorn Market Scrutiny

5. Consumer Behavior

6. Opportunities

7. Roadblocks

8. Key Players

Continued….

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
+1 646-845-9349
email us here


Source: EIN Presswire

Immune Checkpoint Inhibitors Market 2020 Global Trends, Share, Growth, Analysis, Opportunities and Forecast To 2026

PUNE, MAHARASTRA, INDIA, March 3, 2020 /EINPresswire.com/ — The immune checkpoint inhibitor is a drug made of antibodies that unleashes an immune system attack on cancer cells. Checkpoint inhibitors seek to overcome one of cancer’s main defenses against an immune system attack.
Immune system T cells patrol the body constantly for signs of disease or infection. When they encounter another cell, they probe certain proteins on its surface, which serve as insignia of the cell’s identity. Checkpoint inhibitors block normal proteins on cancer cells, or the proteins on T cells. The result is to remove the blinders that prevented T cells from recognizing the cells as cancerous and leading an immune system assault on them.
Three checkpoint inhibitors have received rapid approval from the U.S. Food and Drug Administration for cancer, including ipilimumab, pembrolizumab, and nivolumab.

@Get Free Sample Report at https://www.wiseguyreports.com/sample-request/3792032-global-immune-checkpoint-inhibitors-market-2019-2026

Global Immune Checkpoint Inhibitors Market – Market Dynamics
The rising prevalence of cancer is one of the factor fueling the global immune checkpoint inhibitors market.
According to National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer in the United States and 609,640 people will die from the disease.
The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer.
The number of new cases of cancer is 439.2 per 100,000 men and women per year. The number of cancer deaths is 163.5 per 100,000 men and women per year in the U.S.
According to Cancer Research U.K., There are more than 360,000 new cancer cases in the UK every year, that's nearly 990 every day. The incidence rates for all cancers combined are projected to rise by 2% in the UK between 2014 and 2035, to 742 cases per 100,000 people by 2035.
In U.K, there were around 183,000 new cancer cases in male and around 177,000 new cancer cases in female, in 2015.
Global Immune Checkpoint Inhibitors Market – Segment Analysis
Based on drug class the global market for immune checkpoint inhibitors is broadly segmented as by PD- 1 inhibitors, PD- L1 inhibitors, and CTLA- 4.
Currently PD- 1 inhibitors is the dominant segment and it accounts for approximately XX% of the market, due to the regulatory approval for PD- 1 inhibitors and strategig alliance between companies for clinical collaboration.
For instance, in December 2018, Bristol-Myers Squibb Company and Vedanta Biosciences have signed an agreement for clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.
In October 2018, Sanofi and Regeneron’s have received FDA approval for cemiplimab (REGN-2810), a programmed cell death protein 1 (PD-1) checkpoint inhibitor.
In January 2018, Bristol-Myers Squibb Company and Ono Pharmaceutical Company, Ltd. have signed a global patent license agreement with Merck & Co., Inc. to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda (pembrolizumab).
In July 2015, Bristol-Myers Squibb Company have received European Commission approval for Nivolumab BMS. Nivolumab BMS is for the treatment of locally advanced or metastatic squamous (SQ) non-small cell lung cancer (NSCLC) after prior chemotherapy. Nivolumab is also the first and only PD-1 immune checkpoint inhibitor to demonstrate overall survival (OS) in previously-treated metastatic SQ NSCLC.
Global Immune Checkpoint Inhibitors Market – Geographical Analysis
The global immune checkpoint inhibitors market is segmented into North America, Europe, Asia Pacific, South America and ROW.
North America is dominating the global immune checkpoint inhibitors market, due to increasing regulatory approval for immune checkpoint inhibitors, which is fueling the market growth.
For instance, in November 2018, the Food and Drug Administration (FDA) have approved the checkpoint inhibitor Keytruda (pembrolizumab) for people with hepatocellular carcinoma (HCC), the most common type of cancer that originates in the liver.
In September 2018, the U.S. Food and Drug Administration have approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC. Libtayo works by targeting the cellular pathway known as PD-1 (protein found on the body’s immune cells and some cancer cells).
In May 2017, AstraZeneca have received the US Food and Drug Administration (FDA) approval for Imfinzi (durvalumab) PD-L1. Imfinzi is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC).
Global Immune Checkpoint Inhibitors Market – Competitive Analysis
The strategic alliance between companies for immune checkpoint inhibitors is one of the key factor driving the global immune checkpoint inhibitors market.
For instance, in October 2018, Bristol-Myers Squibb Company and Compugen, have entered into a clinical trial collaboration to evaluate the safety and tolerability of COM701, an investigational anti-PVRIG antibody, in combination with programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab), in patients with advanced solid tumors.
in August 2018, Ono Pharmaceutical Co. Ltd., have entered into the clinical collaboration agreement with Bristol-Myers Squibb Company and Clovis Oncology Inc. to evaluate the combination therapy of ONO/BMS's Opdivo, a human anti- human PD-1 monoclonal antibody, and Clovis' Rubraca8, an inhibitor of poly polymerase (PARP) in multiple tumor types including ovarian cancer, breast cancer and prostate cancer in Japan, South Korea and Taiwan.
In April 2015, MedImmune, and Juno Therapeutics, Inc., have entered into a new collaboration to conduct combination clinical trials in immuno-oncology with one of Juno's investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune's investigational programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor, MEDI4736.

@Enquiry Before Buying https://www.wiseguyreports.com/enquiry/3792032-global-immune-checkpoint-inhibitors-market-2019-2026

Why Purchase the Report?
• Visualize the composition of the immune checkpoint inhibitors market across each indication, in terms of drug class, and by application, highlighting the key commercial assets and players.
• Identify commercial opportunities in immune checkpoint inhibitors market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of the immune checkpoint inhibitors market – level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

The Sage Group Expands Team in North America – Dr. Christine T. Fischette Joins as New Executive Director

Dr. Chrstine Fischette

The Sage Group Inc, leaders in healthcare transaction strategy, today announced that Dr. Christine T. Fischette will join the firm as an Executive Director.

Chris brings both a strong scientific and management background in pharma as well as extensive corporate and deal-making experience.”

— Wayne Pambianchi

NEW YORK, USA, March 3, 2020 /EINPresswire.com/ — The Sage Group, Inc. today announced that Dr. Christine T. Fischette will join the firm as an Executive Director. “We are delighted that Chris has decided to join Sage. Chris will bring her wide-ranging expertise with healthcare and bioscience clients to The Sage Healthcare Group. Chris has a prestigious career in the pharma industry, ranging from startups to large corporate entities, and this will complement our existing skill set at Sage Healthcare.” said Wayne Pambianchi, Executive Director of Sage Healthcare. “Chris brings both a strong scientific background in pharma as well as extensive corporate and deal-making experience.”

Chris received her Ph.D. in Physiology from Rutgers Biomedical Health Sciences.

Since 2010 Chris is the Founder & CEO of BioLinkUp LLC, a Corporate Strategy/Business Development entity, where she specializes in advising companies on growth strategies, business development, partnering / licensing and drug development.

Chris consults for investment banks, venture capitalists, biopharma companies and universities as an independent consultant, and has executed and/or originated deals valued at over $200million. She has spent 25+ years at Roche, Pfizer and Novartis, lastly as Head of Negotiation and Board Director for several therapeutic business units at Novartis where she executed multi-billion dollar deals. She has served as President of a small public biotech firm, and has accumulated wide ranging experience in strategic and operational roles in research, drug development, commercialization, business development and general management.

At Pfizer she orchestrated the entire drug development and marketing process of a therapeutic from formulation selection, through clinical development (IND to NDA) to successful commercialization with net sales reaching $350m, and eventually was Head of Pfizer’s US Commercial Franchise for Diabetes.

She has served on private company Business/Scientific Advisory Boards for therapeutics and devices, and is a faculty member of the BIO Business Development Fundamentals Course offered annually by BIO. She was the Founding member and Chair of the M&A Committee for the USA/Canada Licensing Executive Society (LES), and Co-Chair for the LES NYC Chapter.

She continues as an invited reviewer of grant proposals at Rockefeller University to assess future developmen and commercialization potential, and frequently organizes and speaks at BioPharma panels at industry meetings. She has widespread relationships with senior management within the BioPharma industry, and in her research career has authored over 50 publications in peer-reviewed publications, including Science.

“I am pleased to join The Sage Healthcare Group and to assist them in building on their great industry track record” said Dr. Fischette. “My skills and industry experience will be highly synergistic with Sage Healthcare’s clients, and working together we can achieve great things for our partners and clients in the pharma, diagnostics and medtech sectors, as well as in the financial sector serving the industry.”

About The Sage Healthcare Group, Inc.
The Sage Group Inc and Sage Healthcare Ltd (www.sagehealthcare.com) are leaders in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage Healthcare currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million. The establishment of operations in Europe and Japan, and shortly China, has allowed its clients to reach out beyond their own regions and capture the potential of the global healthcare market.

The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.

The range of services offered includes:
• Strategic alliances and licensing/partnering in and out
• M&A, divestment, buy- and sell- side
• Global product and technology acquisition searches
• Strategic assessment and planning
• Due diligence, technology and molecule assessment, valuation
• New ventures, interim management
• Facilitating investment in R&D and/or company equity through introductions, network and brokering

The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals also have held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Healthcare Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.

The Sage Group can be contacted at any of the offices shown below:

EU Corporate Office
Dr. Bill Mason
Sage Healthcare Ltd.
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX
UK
Phone: +44 1638 500775
Mob: +44 7785 950134
wtm@sagehealthcare.com

US Corporate Office
Mr. Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North, #381
Clinton, NJ 08809
USA
Phone: + 1 646 4123332
Fax: +1 908 2319692
wp@sagehealthcare.com

Dr. Bill Mason
The Sage Group
+447785950134
email us here


Source: EIN Presswire